CN106636141A - 一种罗博卢酮的生物合成基因簇及其应用 - Google Patents
一种罗博卢酮的生物合成基因簇及其应用 Download PDFInfo
- Publication number
- CN106636141A CN106636141A CN201610051232.9A CN201610051232A CN106636141A CN 106636141 A CN106636141 A CN 106636141A CN 201610051232 A CN201610051232 A CN 201610051232A CN 106636141 A CN106636141 A CN 106636141A
- Authority
- CN
- China
- Prior art keywords
- base
- gene cluster
- ketone
- bolu
- luo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091008053 gene clusters Proteins 0.000 title claims abstract description 61
- UURMXICTBNVMJV-UHFFFAOYSA-N Rubrolone Natural products CCCc1nc(C)cc2C3=C(C=C(O)C4=C(OC5OC(C)C(O)C(O)C45O)C3=O)C(=O)c12 UURMXICTBNVMJV-UHFFFAOYSA-N 0.000 title abstract description 7
- PBLXMLFSQXRIOJ-UHFFFAOYSA-N rubrolone Chemical compound O=C1C2=C3C=C(C)NC(CCC)=C3C(=O)C2=CC(=O)C2=C1OC1C2(O)C(O)C(O)C(C)O1 PBLXMLFSQXRIOJ-UHFFFAOYSA-N 0.000 title abstract 6
- 230000001851 biosynthetic effect Effects 0.000 title abstract 5
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 64
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 63
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 229930014626 natural product Natural products 0.000 claims abstract description 21
- 241000187180 Streptomyces sp. Species 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 6
- 239000002585 base Substances 0.000 claims description 80
- 150000002576 ketones Chemical class 0.000 claims description 77
- 239000002773 nucleotide Substances 0.000 claims description 70
- 125000003729 nucleotide group Chemical group 0.000 claims description 70
- 238000003786 synthesis reaction Methods 0.000 claims description 53
- 150000001413 amino acids Chemical class 0.000 claims description 48
- 101150036080 at gene Proteins 0.000 claims description 38
- 241000187759 Streptomyces albus Species 0.000 claims description 24
- 239000013612 plasmid Substances 0.000 claims description 19
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 108020004414 DNA Proteins 0.000 claims description 15
- 230000001580 bacterial effect Effects 0.000 claims description 15
- -1 phenolic ketone Chemical class 0.000 claims description 12
- 150000004788 tropolones Chemical class 0.000 claims description 11
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 239000003513 alkali Substances 0.000 claims description 8
- 230000006870 function Effects 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 241000709400 Ruba Species 0.000 claims description 7
- 241001655322 Streptomycetales Species 0.000 claims description 7
- 210000004027 cell Anatomy 0.000 claims description 7
- YSYKRGRSMLTJNL-URARBOGNSA-N dTDP-alpha-D-glucose Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@@H](O)C1 YSYKRGRSMLTJNL-URARBOGNSA-N 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 101100041250 Clostridium perfringens (strain 13 / Type A) rubR1 gene Proteins 0.000 claims description 5
- 101100202096 Corynebacterium efficiens (strain DSM 44549 / YS-314 / AJ 12310 / JCM 11189 / NBRC 100395) ruvB gene Proteins 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 238000004458 analytical method Methods 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 125000003147 glycosyl group Chemical group 0.000 claims description 5
- 101150098136 rubB gene Proteins 0.000 claims description 5
- 101710146995 Acyl carrier protein Proteins 0.000 claims description 4
- 101100041258 Clostridium perfringens (strain 13 / Type A) rubR2 gene Proteins 0.000 claims description 4
- 101710088194 Dehydrogenase Proteins 0.000 claims description 4
- 102000004867 Hydro-Lyases Human genes 0.000 claims description 4
- 108090001042 Hydro-Lyases Proteins 0.000 claims description 4
- 102000004195 Isomerases Human genes 0.000 claims description 4
- 108090000769 Isomerases Proteins 0.000 claims description 4
- 102000004357 Transferases Human genes 0.000 claims description 4
- 108090000992 Transferases Proteins 0.000 claims description 4
- 238000002474 experimental method Methods 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 230000008065 myocardial cell damage Effects 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 238000007622 bioinformatic analysis Methods 0.000 claims description 3
- 230000008827 biological function Effects 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- 101150084750 1 gene Proteins 0.000 claims description 2
- 102000057234 Acyl transferases Human genes 0.000 claims description 2
- 108700016155 Acyl transferases Proteins 0.000 claims description 2
- 102100033328 Ankyrin repeat domain-containing protein 42 Human genes 0.000 claims description 2
- 101710095468 Cyclase Proteins 0.000 claims description 2
- 101000732369 Homo sapiens Ankyrin repeat domain-containing protein 42 Proteins 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 108700014220 acyltransferase activity proteins Proteins 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 210000000349 chromosome Anatomy 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 229930182478 glucoside Natural products 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000003223 protective agent Substances 0.000 claims description 2
- 238000012163 sequencing technique Methods 0.000 claims description 2
- 229940104230 thymidine Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 12
- 102000004169 proteins and genes Human genes 0.000 abstract description 8
- MDYOLVRUBBJPFM-UHFFFAOYSA-N tropolone Chemical compound OC1=CC=CC=CC1=O MDYOLVRUBBJPFM-UHFFFAOYSA-N 0.000 abstract description 7
- 238000012239 gene modification Methods 0.000 abstract description 3
- 230000005017 genetic modification Effects 0.000 abstract description 3
- 235000013617 genetically modified food Nutrition 0.000 abstract description 3
- 230000007246 mechanism Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000001228 spectrum Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000004321 preservation Methods 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241000187747 Streptomyces Species 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000000855 fermentation Methods 0.000 description 4
- 230000004151 fermentation Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- FSBWLHLWIYLPKF-UHFFFAOYSA-N 2,15,16,17-tetrahydroxy-6,18-dimethyl-8-propyl-19,21-dioxa-7-azapentacyclo[12.7.0.03,11.04,9.015,20]henicosa-1(14),2,4(9),5,7,11-hexaene-10,13-dione Chemical compound CCCc1nc(C)cc-2c1C(=O)c1cc(=O)c3c(OC4OC(C)C(O)C(O)C34O)c(O)c-21 FSBWLHLWIYLPKF-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229910001868 water Inorganic materials 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 238000003512 Claisen condensation reaction Methods 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 241000927129 Streptomyces sp. KIB-H033 Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000005100 correlation spectroscopy Methods 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000003919 heteronuclear multiple bond coherence Methods 0.000 description 2
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 229930001119 polyketide Natural products 0.000 description 2
- 150000003881 polyketide derivatives Chemical class 0.000 description 2
- 229920001470 polyketone Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 108010030975 Polyketide Synthases Proteins 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- BLBVLMPUSLFQNF-UHFFFAOYSA-N S.P(O)(O)(O)=O Chemical class S.P(O)(O)(O)=O BLBVLMPUSLFQNF-UHFFFAOYSA-N 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000011082 depyrogenation Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- WHWDWIHXSPCOKZ-UHFFFAOYSA-N hexahydrofarnesyl acetone Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)=O WHWDWIHXSPCOKZ-UHFFFAOYSA-N 0.000 description 1
- 230000007412 host metabolism Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- LTYOQGRJFJAKNA-IJCONWDESA-N malonyl-coenzyme a Chemical compound O[C@@H]1[C@@H](OP(O)(O)=O)[C@H](CO[P@](O)(=O)O[P@@](O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 LTYOQGRJFJAKNA-IJCONWDESA-N 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000019702 secondary metabolite biosynthetic process Effects 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- MWEMXEWFLIDTSJ-UHFFFAOYSA-M sodium;3-morpholin-4-ylpropane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CCCN1CCOCC1 MWEMXEWFLIDTSJ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/153—Ortho-condensed systems the condensed system containing two rings with oxygen as ring hetero atom and one ring with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/01—Hydro-lyases (4.2.1)
- C12Y402/01046—Hydro-lyases (4.2.1) dTDP-glucose 4,6-dehydratase (4.2.1.46)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/465—Streptomyces
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
本发明提供一种托酚酮类天然产物罗博卢酮的生物合成基因簇,链霉菌Streptomyces sp.CGMCC No.11535,从它们获得罗博卢酮化合物1‑4的制备方法,以其为活性成分的药物组合物,它们在制药中的应用。本发明所提供的包含格罗博卢酮生物合成相关的所有基因和蛋白信息,对了解罗博卢酮天然产物的生物合成机制,为进一步遗传改造提供了材料和知识。本发明所提供的基因及其蛋白质也用来寻找和发现可用于医药、工业或农业的化合物或基因、蛋白。
Description
技术领域:
本发明属于微生物基因工程领域,具体涉及一组托酚酮类天然产物罗博卢酮的生物合成基因簇及其应用。
背景技术:
罗博卢酮为具有A、B、C、D、E五环并构的新骨架天然产物(图1),其中A环是2,3,4,6-四取代的吡啶环,B环为环戊酮,C环为环庚三烯酚酮(tropolone),D环和E环为糖通过糖苷键及碳碳键与环庚三烯酚酮环缩合而成。该化学结构区别于所有已知的天然产物,且到目前为止,还未有其它类似物报道。罗博卢酮A(Rubrolone A)最初是1978年Palleron小组从Streptomyces enchinoruber中分离得到的化合物。微生物次级代谢产物生物合成是由多酶体系参与的,这些多酶体系中的各个酶系按照一定的组织结构协调起作用。聚酮类化合物的生物合成通常是由生物体内的聚酮合酶利用乙酰辅酶A、丙二酰辅酶A和甲基丙二酰辅酶A等二碳单元通过一系列的克莱森缩合(Claisen Condensation)形成聚酮链骨架,然后再经一系列的修饰和环化,最终形成结构各异的聚酮化合物。近年来蓬勃发展起来的组合生物合成技术,为天然产物的发现和药物开发带来了新的机遇。在阐明了自然界的生物合成途径、理解自然界聚酮化合物天然组合生物合成机理的基础上,人们可以采用组合生物合成技术对抗生素的生物合成基因、调控基因进行分子遗传操作和异源表达,不但能够生产“非天然”的天然产物结构类似物,而且还可以提高天然产物的产量,或定向积累所需要的天然产物,为天然产物的发现和药物开发提供化合物结构和生物活性多样化。目前现有技术中没有为罗博卢酮的生产菌链霉菌Streptomyces sp.CGMCC No.11535(Streptomyces sp.KIB-H033)的报道。
发明内容:
本发明的目的在于提供一种罗博卢酮的生物合成基因簇,同时提供链霉菌Streptomyces sp.CGMCC No.11535(KIB-H033),从其中获得的化合物1-4,它们的药物组合物,以及制备方法和在制药中的应用。
为了实现本发明的上述目的,本发明提供了如下的技术方案:
一种托酚酮类天然产物罗博卢酮的生物合成基因簇,其核苷酸序列如SEQ IDNO.1的第6308~28758位的碱基序列所示。
链霉菌Streptomyces sp.CGMCC No.11535。
如所述的一种托酚酮类天然产物罗博卢酮的生物合成基因簇,该生物合成基因簇是从包含有整个罗博卢酮生物合成基因簇的科斯质粒p9B10中测序获得的,该罗博卢酮的生物合成基因簇的核苷酸序列如SEQ ID NO.1的第6308~28758位的碱基序列所示,包含24个基因,具体为:
(1)负责罗博卢酮的酚酮七元环骨架合成的基因,即rubA、rubB、rubC、rubE1、rubE2、rubE3、rubE4、rubE5、rubE6、rubE7、rubE8、rubE9共12个基因:
rubA位于基因簇核苷酸序列SEQ ID NO.1第16318-17253个碱基处,长度为936个碱基对,编码F-420依赖的氧化还原酶,311个氨基酸;
rubB位于基因簇核苷酸序列SEQ ID NO.1第17831-19387个碱基处,长度为1557个碱基对,编码氧化酶,518个氨基酸;
rubC位于基因簇核苷酸序列SEQ ID NO.1第19384-20553个碱基处,长度为1170个碱基对,编码水解酶,389个氨基酸;
rubE1位于基因簇核苷酸序列SEQ ID NO.1第20926-21885个碱基处,长度为960个碱基对,编码III型酮基合成酶,319个氨基酸;
rubE2位于基因簇核苷酸序列SEQ ID NO.1第22167-22442个碱基处,长度为276个碱基对,编码II型PKS酰基载体蛋白,91个氨基酸;
rubE3位于基因簇核苷酸序列SEQ ID NO.1第22597-23517个碱基处,长度为921个碱基对,编码酰基转移酶,306个氨基酸;
rubE4位于基因簇核苷酸序列第23587-23841个碱基处,长度为255个碱基对,编码II型PKS酰基载体蛋白,84个氨基酸;
rubE5位于基因簇核苷酸序列第24281-24775个碱基处,长度为495个碱基对,编码环化/脱氢酶,164个氨基酸;
rubE6位于基因簇核苷酸序列SEQ ID NO.1第24775-25530个碱基处,长度为756个碱基对,编码环化酶,251个氨基酸;
rubE7位于基因簇核苷酸序列SEQ ID NO.1第25527-26147个碱基处,长度为621个碱基对,编码NADH依赖的脱氢酶,206个氨基酸;
rubE8位于基因簇核苷酸序列SEQ ID NO.1第26297-27526个碱基处,长度为1230个碱基对,编码II型PKS酮基合成酶,409个氨基酸;
rubE9位于基因簇核苷酸序列SEQ ID NO.1第27556-28758个碱基处,长度为1203个碱基对,编码II型PKS链延伸因子模块,400个氨基酸;
(2)负责罗博卢酮的糖基合成的基因,即rubS1、rubS2、rubS3、rubS4、rubS5、rubS6、rubS7共7个基因:
rubS1位于基因簇核苷酸序列SEQ ID NO.1第6308-7786个碱基处,长度为1478个碱基对,编码FAD-依赖的氧化还原酶,492个氨基酸;
rubS2位于基因簇核苷酸序列SEQ ID NO.1第8303-8917个碱基处,长度为615个碱基对,编码dTDP-葡糖3,5-异构酶,204个氨基酸;
rubS3位于基因簇核苷酸序列SEQ ID NO.1第9053-9985个碱基处,长度为933个碱基对,dTDP-葡糖4-酮基还原酶,310个氨基酸;
rubS4位于基因簇核苷酸序列SEQ ID NO.1第9982-11013个碱基处,长度为1032个碱基对,编码dTDP-葡糖4,6脱水酶,343个氨基酸;
rubS5位于基因簇核苷酸序列SEQ ID NO.1第11030-11899个碱基处,长度为870个碱基对,葡糖-1磷酸-胸苷转移酶,289个氨基酸;
rubS6位于基因簇核苷酸序列SEQ ID NO.1第11921-12757个碱基处,长度为837个碱基对,编码NAD依赖的异构酶/脱水酶,278个氨基酸;
rubS7位于基因簇核苷酸序列SEQ ID NO.1第12868-14022个碱基处,长度为1155个碱基对,编码糖苷转移酶,384个氨基酸;
(3)负责罗博卢酮调控子蛋白的基因,即rubR1、rubR2共2个基因:
rubR1位于基因簇核苷酸序列SEQ ID NO.1第14232-15269个碱基处,长度为1038个碱基对,编码SARP家族转录调控子,345个氨基酸;
rubR2位于基因簇核苷酸序列第15329-15676个碱基处,长度为348个碱基对,编码转录调控蛋白,115个氨基酸;
(4)其它功能尚未明确的蛋白,rubN共1个基因:
rubN位于基因簇核苷酸序列SEQ ID NO.1第7783-8190个碱基处,长度为408个碱基对,编码未知功能蛋白,135个氨基酸。
包含有所述的一种托酚酮类天然产物罗博卢酮的生物合成基因簇核苷酸序列SEQID NO.1的第6308~28758位的碱基序列,或者包含有以权利要求2所述的链霉菌Streptomyces sp.CGMCC No.11535中提取的DNA序列的重组菌株S.albus/9B10。
包含有所述的一种托酚酮类天然产物罗博卢酮的生物合成基因簇核苷酸序列SEQID NO.1的第6308~28758位的碱基序列,或者包含有以所述的链霉菌Streptomycessp.CGMCC No.11535中提取的DNA序列的表达载体。
如下结构式所示的罗博卢酮及其类似物1-4,
所述的罗博卢酮的生物合成基因簇在制备罗博卢酮及其类似物中的应用。
制备所述的罗博卢酮化合物1-4的方法,该方法包括将权利要求1所述的SEQ IDNO.1所示的核苷酸序列整合到链霉菌S.albus染色体中异源表达产生化合物1,2,3,4,
如所述的制备方法,该方法包括如下步骤:
(1)罗博卢酮生物合成基因簇测序以及序列生物信息学分析:
先对罗博卢酮产生菌链霉菌链霉菌Streptomyces sp.CGMCC No.11535进行大量基因组DNA提取,然后对权利要求1所述的包含有罗博卢酮生物合成基因簇序列为SEQ IDNO.1的科斯质粒进行测序,得到插入片段大约37Kb的基因组序列包含SEQ ID NO.1的第6308~28758位的碱基序列,通过生物信息学软件及数据库比对分析,所测序科斯质粒包含了整个罗博卢酮生物合成基因簇,该基因簇包含有24个开放阅读框,包括负责罗博卢酮的酚酮七元环骨架合成的基因,即rubA、rubB、rubC、rubE1、rubE2、rubE3、rubE4、rubE5、rubE6、rubE7、rubE8、rubE9共12个基因,负责罗博卢酮的糖基合成的基因,即rubS1、rubS2、rubS3、rubS4、rubS5、rubS6、rubS7共7个基因;负责罗博卢酮调控子蛋白的基因,即rubR1、rubR2共2个基因;还有一个未知功能的基因rubN,利用数据库比对的方法,分析这24个开放阅读框的基因信息,并找到与其相类似的基因序列,从而推测各开放阅读框的生物功能;
(2)包含整个罗博卢酮生物合成基因簇的科斯质粒p9B10的异源表达:
将包含有完整的罗博卢酮生物合成基因簇序列为SEQ ID NO.1的科斯质粒p9B10与异源宿主链霉菌S.albus进行接合转移实验得到了重组菌株S.albus 9B10,通过在发酵培养基中培养,表达出化合物1,2,3,4。
一种托酚酮类天然产物罗博卢酮的生物合成基因簇或链霉菌Streptomycessp.CGMCC No.11535,包括用所述的表达载体转化的寄主细胞,培养转化体,从培养物获得重组菌株S.albus 9B10的步骤的方法制备。
药物组合物,其中含有化合物1-4或其药用盐作为有效成分,并含有常规药用载体。
所述的化合物罗博卢酮及其类似物在制备预防或治疗心肌细胞损伤疾病的药物中、抗氧化剂中、心肌细胞损伤保护剂中、抗自由基剂中的应用。
本发明的链霉菌Streptomyces sp.CGMCC No.11535(于2015年10月23日保藏在中国微生物菌种保藏管理委员会普通微生物中心,保藏地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所。来源于,由中国科学院昆明植物研究所提供的生物材料:KIB-H033)。
附图说明:
图1是罗博卢酮A(rubrolone A,2)和罗博卢酮B(rubrolone B,1)的化学结构式。
图2是Streptomyces sp.KIB-H033中罗博卢酮生物合成基因簇。
图3是包含有罗博卢酮生物合成基因簇的p9B10整合到异源宿主链霉菌S.albus得到的重组菌株S.albus 9B10在发酵培养基中发酵的发酵产物的HPLC分析图:I野生型S.albus;II重组菌株S.albus 9B10;1,2,3,4表示相应的化合物。
图4A-图4E是本发明新化合物1的核磁共振谱的结果图,依次为H谱,C谱,COSY谱,HSQC谱和HMBC谱。
图5A-图5E是新化合物3的核磁共振谱的结果,依次为H谱,C谱,COSY谱,HSQC谱和HMBC谱。
具体实施方式:
以下结合附图,用本发明的实施例来对本发明做进一步的说明,但并不以此来限定本发明。
实施例1:
1.罗博卢酮生物合成基因簇测序以及序列生物信息学分析:
通过对包含有罗博卢酮生物合成基因簇序列为SEQ ID NO.1的科斯质粒进行测序,得到插入片段大约37Kb的基因组序列SEQ ID NO.1的第6308~28758位的碱基序列,通过生物信息学软件及数据库比对分析,所测序科斯质粒包含了整个罗博卢酮生物合成基因簇,该基因簇全长大约22Kb,分析该基因簇包含有24个开放阅读框(open reading frames,ORFs),包括负责罗博卢酮的酚酮七元环骨架合成的基因,即rubA、rubB、rubC、rubE1、rubE2、rubE3、rubE4、rubE5、rubE6、rubE7、rubE8、rubE9共12个基因,负责罗博卢酮的糖基合成的基因,即rubS1、rubS2、rubS3、rubS4、rubS5、rubS6、rubS7共7个基因;负责罗博卢酮调控子蛋白的基因,即rubR1、rubR2共2个基因;还有一个未知功能的基因rubN。利用数据库比对的方法,分析这24个开放阅读框的基因信息,并找到与其相类似的基因序列,从而推测各开放阅读框的生物功能。具体的罗博卢酮生物合成基因簇的分析如图2所示。
(2)包含整个罗博卢酮生物合成基因簇的科斯质粒p9B10的异源表达:
将包含有完整的罗博卢酮生物合成基因簇序列为SEQ ID NO.1的科斯质粒p9B10与异源宿主链霉菌S.albus进行接合转移实验得到了重组菌株S.albus 9B10,通过在发酵培养基中培养,表达出化合物1,2,3,4。
以下进一步提供具体实施例,这些实施实例有助于理解本发明,仅用作说明而不限制本发明的应用范围。
实施例2
链霉菌Streptomyces sp.CGMCC No.11535(于2015年10月23日保藏在中国微生物菌种保藏管理委员会普通微生物中心,保藏地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所。来源于中国科学院昆明植物所编号为KIB-H033)。
Streptomyces sp.CGMCC No.11535作为典型的链霉菌,其基内菌丝分枝,气生菌丝稍粗,部分气生菌丝分化为螺旋形的孢子丝。同时在培养基里能产生红颜色的化合物。其DNA的G+C含量为71%左右,具有典型的链霉菌属的特征。
罗博卢酮产生菌链霉菌链霉菌Streptomyces sp.CGMCC No.11535(KIB-H033)大量基因组DNA提取:
菌丝培养:用TSB液体培养基50ml于28℃250rpm摇床培养48h。溶菌:于50ml离心管3750rpm离心,15min收集菌丝,用SET buffer(葡萄糖0.3mol/L(10.3%)Tris-HCl 25mmol/L EDTA 25mmol/L pH8.0)洗、离心收集菌体。加5ml SET缓冲液,使菌体悬浮分散,加入溶菌酶至1mg/ml,37℃水浴保温约45min,每15min颠倒混匀一次。去蛋白:加入140μl蛋白酶K,颠倒混匀,再加600μl 10%的SDS,混匀,在50℃温浴2-5h,每30min颠倒一次。蛋白酶K终浓度为0.5mg/ml,SDS为1%。加2ml 5M NaCl,混匀,再加5ml氯仿,于室温混匀30min以上。然后4500g离心30min。沉淀DNA:上清倒入小烧杯,加0.6倍体积异丙醇,颠倒混匀,用灭菌玻棒将总DNA搅出,用70%乙醇清洗。室温稍干燥后立即溶于1-2ml TE中。
实施例3
罗博卢酮产生菌链霉菌Streptomyces sp.CGMCC No.11535(KIB-H033)基因组文库的建立:
首先通过一系列的稀释实验确定了限制性核酸内切酶Mbo I的用量,在50μL体系中,含有5μL的链霉菌Streptomyces sp.CGMCC No.11535基因组DNA,5μL的10×反应缓冲液和7.5μL稀释度为10-2的Sau3A I,其终止反应为2.5μL 15mM EDTA和合适的上样缓冲液。在此基础上通过大量部分酶切得到略大于40kb的基因组DNA片段,用去磷酸化酶进行去磷酸化处理。
用于构建文库的载体pJTU2554质粒先用限制性核酸内切酶Hpa I从两个cos序列中间切开,然后进行去磷酸化处理,再从多克隆位点处用限制性核酸内切酶Bam HI切开,获得两个臂。处理后的载体与之前制备的部分酶切的约40kb的基因组DNA片段连接过夜,连接体系为10μL,含有2.0μg制备的基因组DNA片段和0.50μg处理后的pJTU2554质粒,2μL的10×Buffer,1U的T4连接酶。连接产物70℃处理15分钟,使连接酶失活。从-80℃冰箱中取出一管包装混合物(50μL)置于冰上,将包装混合物在指间迅速融化,小心吸取一半包装混合物(25μL)至一个新的离心管中,加入10μL热处理后的连接产物,其余包装混合物于-80℃保存。小心混匀,30℃温浴90分钟,加入另外一半包装混合物(25μL),30℃温浴继续90分钟。加入500μL噬菌体稀释缓冲液(100mmol/L NaCl,10mmol/L MgCl2,10mmol/L pH8.3Tris-HCl),再加入25μL氯仿,轻轻混匀,得包装液,于4℃保存。
将冻存于-80℃的菌株E.coli XL1-blue涂布在LB培养基上复苏。包装反应前一天,挑取单克隆接种于LB培养基中(添加0.2%麦芽糖和10mM MgSO4),37℃振荡培养过夜,包装反应 当天,取5mL过夜培养的菌液加入到50mL新鲜的LB培养基中(添加0.2%麦芽糖和10mM MgSO4),37℃,200rpm振荡至培养物OD600达到0.8-1时,4℃保存备用,得宿主菌液。取100μL如上处理的宿主菌液和100μL适度稀释的包装液轻轻混匀,于37℃温浴15分钟,然后涂布于含有100μg/mL氨苄青霉素和50μg/mL卡那霉素的LB平板上,37℃培养过夜。将长出来的单个克隆子,用无菌牙签点种于23块含以上上述抗生素的LB培养基的96孔板上,37℃培养过夜,加入终浓度为20%的甘油,混合均匀,置于-80℃保存。
实施例4
从罗博卢酮产生菌(链霉菌Streptomyces sp.CGMCC No.11535)基因组文库中筛选含有罗博卢酮生物合成基因的阳性克隆子:
通过分析罗博卢酮的结构以及相关文献的报道,用dTDP-葡糖4,6脱水酶基因做筛选引物(表1)进行PCR来筛选,从2000个克隆子中得到4个阳性克隆子,其中得到一个包含完整罗博卢酮生物合成基因簇的阳性克隆p9B10,其核苷酸序列如SEQ ID NO.1所示,罗博卢酮的生物合成基因簇的核苷酸序列如SEQ ID NO.1所示序列的第6308~28758位的碱基序列所示。
表1:文库筛选引物
实施例5
将包含有罗博卢酮的生物合成基因簇的科斯质粒p9B10在异源宿主链霉菌S.albus中进行表达:
将含有p9B10的转化菌株E.coli ET12567/pUZ8002/p9B10接种于4mL的LB+100μg/mL Amp+50μg/mL Apr+25μg/mL Cm+50μg/mL Kan液体培养基中,37℃培养14h后,取100μL菌液转接于10mL相同培养基中培养至OD为0.4,离心收集菌体,用不含任何抗生素的LB液体培养基洗涤2次,洗去抗生素,离心浓缩菌体,备用。与此同时,灭菌水收集S.albus孢子,经过滤器过滤后,4000rpm离心15min,弃上清,加入适量LB培养基悬浮孢子,置于50℃水浴中热激10分钟。将转化菌株E.coli ET12567/pUZ8002/p9B10与S.albus孢子按照体积比1:1比例混合,涂布于MS+MgCl2(终浓度为20mmol/L)固体平板上(MS:大豆粉20g/L,甘露醇20g/L,琼脂粉20g/L,pH7.0~7.2,使用去离子水配制,和定 容)。16~20h后,用1mL H2O+30μL100μg/mL Nal+20μL50μg/mL Apr进行药物覆盖。大约在30℃培养3~4天后即可看到接合转移子,该接合转移子即为转入p9B10的链霉菌S.albus,命名为重组菌株S.albus 9B10。
接合转移子—重组菌株S.albus 9B10在MS+50μg/mL Apr平板上培养5~7d后,挑取适量菌丝体分别接种入50mL TSB种子培养基(胰蛋白胨17g/L,植物蛋白胨3g/L,氯化钠5g/L,磷酸氢二钾2.5g/L,葡萄糖2.5g/L,pH7.0~7.2),在温度为28℃,转速为250rpm的摇床上摇瓶2天后分别取3ml菌液转接到50ml PTM发酵培养基(糊精40g/L,乳糖40g/L,酵母提取粉5g/L,MOPS sodium salt 20g/L;pH7.0~7.2)中继续发酵培养4天,得到发酵产物。发酵产物离心后,上清过滤取样进行HPLC检测。HPLC分析条件为:使用YMC-Triart C18(250×4.6mm,5μ)分析柱;A相组成为H2O,B相组成为甲醇。流速为1ml/min,HPLC分析的检测波长为304nm。HPLC走样程序:0-20min,10%-100%B相;20-24min,100%B相;24-28min,10%B相。结果如图3所示,从图3可以看出,野生型的S.albus不能产生化合物1,2,3,4,而重组菌株S.albus 9B10能够产生化合物1,2,3,4。其具体结构如图1所示,新的化合物1、3的核磁共振谱如图4A-图4E和图5A-图5E所示。
本发明SEQ ID NO.1(序列表)所示序列的第6308~28758位的碱基序列的互补序列可根据DNA碱基互补原则随时得到。且第6308~28758位的核苷酸序列或部分核苷酸序列可以通过聚合酶链式反应(PCR)或用合适的限制性内切酶酶切相应的DNA或DNA体外合成技术或使用其他合适的技术得到。本发明提供了得到至少包含部分SEQ ID NO.1所示序列的第6308~28758位中DNA序列的重组DNA载体的途径。
本发明还提供了创制罗博卢酮生物合成基因被阻断或异源表达等其他基因改造的途径,至少其中之一的基因包含SEQ ID NO.1所示序列的第6308~28758位中DNA片段。
本发明所提供的核苷酸序列或部分核苷酸序列,可使用PCR探针法或Southern杂交等技术,从其他生物体重筛选获得罗博卢酮的生物合成基因簇同源基因。
本发明提供的核苷酸序列或部分核苷酸序列,可用于Streptomyces sp.CGMCCNo.11535基因组文库中定位更多的文库质粒。这些文库质粒至少包括本发明中的部分序列,也包含Streptomyces sp.CGMCC No.11535基因组中邻近区域未克隆DNA。
包含本发明所提供的核苷酸序列或至少部分核苷酸序列的DNA片段,可以被体内外突变等修饰,包括插入、置换、缺失、易错聚合酶链式反应、位点特异性突变、不同序列重组、定向进化等。
包含本发明所提供的核苷酸序列或部分核苷酸序列的克隆,可以通过合适表达系统在外源宿主中表达生产相应酶或者提高生物活性化合物产量。这些外源宿主包括大肠杆菌、链霉菌、假单胞菌、芽孢杆菌、酵母及动植物等。
本发明提供的氨基酸序列可以用于分离所需蛋白并可用于抗体制备。
包含本发明所提供的氨基酸序列或者部分序列的多肽,可能在去除或者替代某些氨基酸之后仍有生物活性甚至新的生物活性,或提高了产量或优化了蛋白动力学特征或其他致力于得到的性质。
包含本发明所提供的核苷酸序列或部分核苷酸序列的基因或基因簇可以在异源宿主中表达及揭示它们在宿主代谢中的功能。
包含本发明所提供核苷酸序列或部分核苷酸序列的基因或基因簇可以通过DNA重组技术构建重组载体,以获得新型生物合成途径,也可以通过插入、置换、缺失或失活,进而获得其他基于生物合成途径的新结构化合物。
总之,本发明所提供的包含格罗博卢酮生物合成相关的所有基因和蛋白信息,可以帮助人们理解罗博卢酮天然产物的生物合成机制,为进一步遗传改造提供了材料和知识。本发明所提供的基因及其蛋白质也可以用来寻找和发现可用于医药、工业或农业的化合物或基因、蛋白。
实施例6:
活性测定:
H2O2诱导乳鼠心肌细胞损伤的保护作用:
将在DMED(Dulbeco’s Modified Eagle Medium)培养基里生长的心肌细胞以105/ml的密度接种于96孔培养板,37℃,5%CO2孵育箱中培养12h后,分组加入单体化合物到不同的孔中,浓度为10μM,同时加入卡维地洛为对照。加入化合物24h后再将细胞暴露在600μM的H2O2中24h.酶标仪检测490nm波长的吸光度值。每孔OD值减去空白孔OD值为测试孔OD值。活细胞与OD值成正比。每个化合物设3个复孔,取其平均值。
化合物1-4具有良好的对H2O2诱导乳鼠心肌细胞损伤的保护作用,见表2。
表2:化合物1-4对H2O2诱导乳鼠心肌细胞损伤的保护作用
数据表现形式为平均值±标准偏差。a:独立样本T检验*p<0.05**p<0.01b:阳性对照。
实施例7:
上述实施例所得化合物1-4,加入4%的硫酸乙醇溶液,PH=4,过滤,干燥,制成硫酸盐化合物1-4。
实施例8:
上述实施例所得化合物1-4,加入4%的盐酸溶液,PH=4,过滤,干燥,制成盐酸盐化合物1-4。
实施例9:
上述实施例所得化合物1-4,加入4%的酒石酸溶液,PH=4,过滤,干燥,制成酒石酸盐化合物1-2。
实施例10:
上述实施例所得化合物1-4,加入4%的柠檬酸溶液,PH=4,过滤,干燥,制成柠檬酸盐化合物1-2。
实施例11:
片剂:将上述实施例所得化合物1-4或所得的盐10mg,乳糖180mg,淀粉55mg,硬脂酸镁5mg、乳糖和淀粉混和,用水均匀湿润、把湿润后的混合物过筛并干燥,再过筛,加入硬脂酸镁,然后将混合物压片,每片重250mg,化合物含量为10mg。
实施例12:
安瓿剂:将上述实施例所得化合物1-4或所得的盐2mg,氯化钠10mg,溶解于适量的注射用水中,过滤所得溶液,在无菌条件下装入安瓿瓶中。
实施例13:
注射用冻干剂:上述实施例所得化合物1-4或所得的盐10mg,碳酸氢钠2mg,甘露醇252mg。
制备方法:将碳酸氢钠、甘露醇,加注射用水溶解,加活性碳吸附30min除热原,过滤除去活性碳,在滤液中加入化合物或其盐,超声处理使溶解,用1N盐酸调节PH为5.0-7.0,微孔滤膜滤过,加注射用水,分装,冷冻干燥,上塞,轧盖,即得。
实施例14:
胶囊剂:上述实施例所得化合物1-4或所得的盐10mg,乳糖187mg,硬脂酸镁3mg;制备方法:将化合物或其盐与助溶剂混和,过筛,均匀混合,把得到的混合物装入硬明胶胶囊,每个胶囊重200mg,活性成分含量为10mg。
Claims (12)
1.一种托酚酮类天然产物罗博卢酮的生物合成基因簇,其核苷酸序列如SEQ ID NO.1的第6308~28758位的碱基序列所示。
2.链霉菌Streptomyces sp.CGMCC No.11535。
3.如权利要求1所述的一种托酚酮类天然产物罗博卢酮的生物合成基因簇,其特征在于该生物合成基因簇是从包含有整个罗博卢酮生物合成基因簇的科斯质粒p9B10中测序获得的,该罗博卢酮的生物合成基因簇的核苷酸序列如SEQ ID NO.1的第6308~28758位的碱基序列所示,包含24个基因,具体为:
(1)负责罗博卢酮的酚酮七元环骨架合成的基因,即rubA、rubB、rubC、rubE1、rubE2、rubE3、rubE4、rubE5、rubE6、rubE7、rubE8、rubE9共12个基因:
rubA位于基因簇核苷酸序列SEQ ID NO.1第16318-17253个碱基处,长度为936个碱基对,编码F-420依赖的氧化还原酶,311个氨基酸;
rubB位于基因簇核苷酸序列SEQ ID NO.1第17831-19387个碱基处,长度为1557个碱基对,编码氧化酶,518个氨基酸;
rubC位于基因簇核苷酸序列SEQ ID NO.1第19384-20553个碱基处,长度为1170个碱基对,编码水解酶,389个氨基酸;
rubE1位于基因簇核苷酸序列SEQ ID NO.1第20926-21885个碱基处,长度为960个碱基对,编码III型酮基合成酶,319个氨基酸;
rubE2位于基因簇核苷酸序列SEQ ID NO.1第22167-22442个碱基处,长度为276个碱基对,编码II型PKS酰基载体蛋白,91个氨基酸;
rubE3位于基因簇核苷酸序列SEQ ID NO.1第22597-23517个碱基处,长度为921个碱基对,编码酰基转移酶,306个氨基酸;
rubE4位于基因簇核苷酸序列第23587-23841个碱基处,长度为255个碱基对,编码II型PKS酰基载体蛋白,84个氨基酸;
rubE5位于基因簇核苷酸序列第24281-24775个碱基处,长度为495个碱基对,编码环化/脱氢酶,164个氨基酸;
rubE6位于基因簇核苷酸序列SEQ ID NO.1第24775-25530个碱基处,长度为756个碱基对,编码环化酶,251个氨基酸;
rubE7位于基因簇核苷酸序列SEQ ID NO.1第25527-26147个碱基处,长度为621个碱基对,编码NADH依赖的脱氢酶,206个氨基酸;
rubE8位于基因簇核苷酸序列SEQ ID NO.1第26297-27526个碱基处,长度为1230个碱基对,编码II型PKS酮基合成酶,409个氨基酸;
rubE9位于基因簇核苷酸序列SEQ ID NO.1第27556-28758个碱基处,长度为1203个碱基对,编码II型PKS链延伸因子模块,400个氨基酸;
(2)负责罗博卢酮的糖基合成的基因,即rubS1、rubS2、rubS3、rubS4、rubS5、rubS6、rubS7共7个基因:
rubS1位于基因簇核苷酸序列SEQ ID NO.1第6308-7786个碱基处,长度为1478个碱基对,编码FAD-依赖的氧化还原酶,492个氨基酸;
rubS2位于基因簇核苷酸序列SEQ ID NO.1第8303-8917个碱基处,长度为615个碱基对,编码dTDP-葡糖3,5-异构酶,204个氨基酸;
rubS3位于基因簇核苷酸序列SEQ ID NO.1第9053-9985个碱基处,长度为933个碱基对,dTDP-葡糖4-酮基还原酶,310个氨基酸;
rubS4位于基因簇核苷酸序列SEQ ID NO.1第9982-11013个碱基处,长度为1032个碱基对,编码dTDP-葡糖4,6脱水酶,343个氨基酸;
rubS5位于基因簇核苷酸序列SEQ ID NO.1第11030-11899个碱基处,长度为870个碱基对,葡糖-1磷酸-胸苷转移酶,289个氨基酸;
rubS6位于基因簇核苷酸序列SEQ ID NO.1第11921-12757个碱基处,长度为837个碱基对,编码NAD依赖的异构酶/脱水酶,278个氨基酸;
rubS7位于基因簇核苷酸序列SEQ ID NO.1第12868-14022个碱基处,长度为1155个碱基对,编码糖苷转移酶,384个氨基酸;
(3)负责罗博卢酮调控子蛋白的基因,即rubR1、rubR2共2个基因:
rubR1位于基因簇核苷酸序列SEQ ID NO.1第14232-15269个碱基处,长度为1038个碱基对,编码SARP家族转录调控子,345个氨基酸;
rubR2位于基因簇核苷酸序列第15329-15676个碱基处,长度为348个碱基对,编码转录调控蛋白,115个氨基酸;
(4)其它功能尚未明确的蛋白,rubN共1个基因:
rubN位于基因簇核苷酸序列SEQ ID NO.1第7783-8190个碱基处,长度为408个碱基对,编码未知功能蛋白,135个氨基酸。
4.包含有权利要求1所述的一种托酚酮类天然产物罗博卢酮的生物合成基因簇核苷酸序列SEQ ID NO.1的第6308~28758位的碱基序列,或者包含有以权利要求2所述的链霉菌Streptomyces sp.CGMCC No.11535中提取的DNA序列的重组菌株S.albus 9B10。
5.包含有权利要求1所述的一种托酚酮类天然产物罗博卢酮的生物合成基因簇核苷酸序列SEQ ID NO.1的第6308~28758位的碱基序列,或者包含有以权利要求2所述的链霉菌Streptomyces sp.CGMCC No.11535中提取的DNA序列的表达载体。
6.如下结构式所示的罗博卢酮及其类似物1-4,
7.权利要求1所述的罗博卢酮的生物合成基因簇在制备罗博卢酮及其类似物中的应用。
8.制备权利要求6所述的罗博卢酮化合物1-4的方法,该方法包括将权利要求1所述的SEQ ID NO.1所示的核苷酸序列整合到链霉菌S.albus染色体中异源表达产生化合物1,2,3,4,
9.如权利要求8所述的制备方法,其特征在于该方法包括如下步骤:
(1)罗博卢酮生物合成基因簇测序以及序列生物信息学分析:
先对罗博卢酮产生菌链霉菌链霉菌Streptomyces sp.CGMCC No.11535进行大量基因组DNA提取,然后对权利要求1所述的包含有罗博卢酮生物合成基因簇序列为SEQ ID NO.1的科斯质粒进行测序,得到插入片段大约37Kb的基因组序列包含SEQ ID NO.1的第6308~28758位的碱基序列,通过生物信息学软件及数据库比对分析,所测序科斯质粒包含了整个罗博卢酮生物合成基因簇,该基因簇包含有24个开放阅读框,包括负责罗博卢酮的酚酮七元环骨架合成的基因,即rubA、rubB、rubC、rubE1、rubE2、rubE3、rubE4、rubE5、rubE6、rubE7、rubE8、rubE9共12个基因,负责罗博卢酮的糖基合成的基因,即rubS1、rubS2、rubS3、rubS4、rubS5、rubS6、rubS7共7个基因;负责罗博卢酮调控子蛋白的基因,即rubR1、rubR2共2个基因;还有一个未知功能的基因rubN,利用数据库比对的方法,分析这24个开放阅读框的基因信息,并找到与其相类似的基因序列,从而推测各开放阅读框的生物功能;
(2)包含整个罗博卢酮生物合成基因簇的科斯质粒p9B10的异源表达:
将包含有完整的罗博卢酮生物合成基因簇序列为SEQ ID NO.1的科斯质粒p9B10与异源宿主链霉菌S.albus进行接合转移实验得到了重组菌株S.albus 9B10,通过在发酵培养基中培养,表达出化合物1,2,3,4。
10.一种托酚酮类天然产物罗博卢酮的生物合成基因簇或链霉菌Streptomycessp.CGMCC No.11535,包括用权利要求5所述的表达载体转化的寄主细胞,培养转化体,从培养物获得重组菌株S.albus 9B10的步骤的方法制备。
11.药物组合物,其中含有权利要求6的化合物1-4或其药用盐作为有效成分,并含有常规药用载体。
12.权利要求6所述的化合物罗博卢酮及其类似物在制备预防或治疗心肌细胞损伤疾病的药物中、抗氧化剂中、心肌细胞损伤保护剂中、抗自由基剂中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610051232.9A CN106636141B (zh) | 2016-01-26 | 2016-01-26 | 一种罗博卢酮的生物合成基因簇及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610051232.9A CN106636141B (zh) | 2016-01-26 | 2016-01-26 | 一种罗博卢酮的生物合成基因簇及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106636141A true CN106636141A (zh) | 2017-05-10 |
CN106636141B CN106636141B (zh) | 2019-08-13 |
Family
ID=58848658
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610051232.9A Active CN106636141B (zh) | 2016-01-26 | 2016-01-26 | 一种罗博卢酮的生物合成基因簇及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106636141B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106916835A (zh) * | 2015-12-24 | 2017-07-04 | 武汉臻智生物科技有限公司 | 化合物的生物合成基因簇及其应用 |
CN108822119A (zh) * | 2018-06-25 | 2018-11-16 | 中国医学科学院医药生物技术研究所 | 具有自噬激活活性的红醇酮类化合物、其制备方法及其制药应用 |
CN111607603A (zh) * | 2020-05-19 | 2020-09-01 | 武汉大学 | Hangtaimycin生物合成基因簇及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4057553A (en) * | 1976-08-26 | 1977-11-08 | Hoffmann-La Roche Inc. | Certain pyrano-furo-azuleno-pyridines |
CN105585573B (zh) * | 2016-01-26 | 2018-04-17 | 中国科学院昆明植物研究所 | 一种托酚酮类化合物及其药物组合物和其制备方法与应用 |
-
2016
- 2016-01-26 CN CN201610051232.9A patent/CN106636141B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4057553A (en) * | 1976-08-26 | 1977-11-08 | Hoffmann-La Roche Inc. | Certain pyrano-furo-azuleno-pyridines |
CN105585573B (zh) * | 2016-01-26 | 2018-04-17 | 中国科学院昆明植物研究所 | 一种托酚酮类化合物及其药物组合物和其制备方法与应用 |
Non-Patent Citations (2)
Title |
---|
YIJUN YAN等: "Non-enzymatic pyridine ring formation in the biosynthesis of the rubrolone tropolone alkaloids", 《NATURE COMMUNICATIONS》 * |
刘小玲等: "环庚三烯酚酮类化合物的研究进展", 《天然产物研究与开发》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106916835A (zh) * | 2015-12-24 | 2017-07-04 | 武汉臻智生物科技有限公司 | 化合物的生物合成基因簇及其应用 |
CN106916835B (zh) * | 2015-12-24 | 2022-08-12 | 武汉合生科技有限公司 | 化合物的生物合成基因簇及其应用 |
CN108822119A (zh) * | 2018-06-25 | 2018-11-16 | 中国医学科学院医药生物技术研究所 | 具有自噬激活活性的红醇酮类化合物、其制备方法及其制药应用 |
CN111607603A (zh) * | 2020-05-19 | 2020-09-01 | 武汉大学 | Hangtaimycin生物合成基因簇及其应用 |
CN111607603B (zh) * | 2020-05-19 | 2021-12-17 | 武汉大学 | Hangtaimycin生物合成基因簇及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN106636141B (zh) | 2019-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105087456B (zh) | 一种产特定分子量透明质酸的重组枯草芽孢杆菌构建的方法 | |
CN103468625B (zh) | 一种冰城链霉菌的基因阻断突变菌及其制备方法和应用 | |
CN106497827B (zh) | 一种定向生产抗结核活性和抗肿瘤活性化合物的基因工程菌株及其应用 | |
CN109735556A (zh) | 引导糖基转移酶基因的用途 | |
EP3385386A1 (en) | Carrimycin biosynthetic gene cluster | |
CN106636141B (zh) | 一种罗博卢酮的生物合成基因簇及其应用 | |
CN105368767A (zh) | D-丙氨酸缺陷型筛选表达纤维二糖-2-差向异构酶的重组枯草芽孢杆菌及其构建方法 | |
CN102586146B (zh) | 一种产生庆大霉素C1a的工程菌及其构建方法 | |
CN103215281B (zh) | 一种格瑞克霉素和p-1894b的生物合成基因簇及其应用 | |
CN107881140A (zh) | 一株高产甘露醇的肠膜明串珠菌突变菌株及其应用方法 | |
CN108546722A (zh) | 一种利用丹参功能基因从头生物合成迷迭香酸的方法 | |
CN101363022B (zh) | 替曲卡星a的生物合成基因簇及其应用 | |
CN103555646B (zh) | 一种共表达l-阿拉伯糖异构酶基因和甘露糖-6-磷酸异构酶的基因工程菌 | |
CN102703495A (zh) | 提高链霉菌抗生素产量的方法及其质粒 | |
CN103882005A (zh) | 链霉菌菌株spc6-50-1的诱变筛选方法及应用 | |
CN106399218A (zh) | 一株枯草芽孢杆菌工程菌及其应用 | |
CN102660488A (zh) | 一种促进美达霉素生物合成的基因工程菌及其应用 | |
CN116478878A (zh) | 一种高产核黄素的枯草芽孢杆菌及其应用 | |
CN101914452B (zh) | 石杉碱甲高产菌株tcm-01 | |
CN106916836B (zh) | 化合物的生物合成基因簇及其应用 | |
CN102719388A (zh) | 提高链霉菌抗生素产量的方法及其质粒 | |
CN104263738A (zh) | Fas ii抑制剂abx的生物合成基因簇 | |
CN113337432B (zh) | 一种产吡咯喹啉醌的食甲基菌及其应用 | |
CN106190854B (zh) | 一种荒漠拟孢囊菌和奥利万星中间体的制备方法 | |
CN110423790A (zh) | 一种抗真菌四霉素b定向高产的代谢工程方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |